Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to Clinical Practice.

Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to Clinical Practice.

Early¬†medical¬†response (ECR) is a brand new endpoint to decide whether or not a drug needs to be authorized for community-acquired bacterial pneumonia in the United States. The Omadacycline for Pneumonia Treatment In the Community (OPTIC) section III research demonstrated noninferiority of omadacycline to moxifloxacin utilizing this endpoint. This research describes the efficiency of the ECR … Read more